Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Chronic Renal Failure

Free Subscription Articles published in Lancet Retrieve available abstracts of 13 articles: HTML format

Single Articles

November 2025
1. HERRINGTON WG, Judge PK, Grams ME, Wanner C, et al
   Chronic kidney disease.
   Lancet. 2025 Nov 25:S0140-6736(25)01942-7. doi: 10.1016/S0140-6736(25)01942.
   PubMed     Abstract available
   
   
   
2. THE LANCET
   Chronic kidney disease: breaking the silence.
   Lancet. 2025;406:2393.
   PubMed    
   
   
   
3. HEERSPINK HJL, Cardona JF, Jolly S, Pergola PE, et al
   Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
   Lancet. 2025 Nov 8:S0140-6736(25)02014-8. doi: 10.1016/S0140-6736(25)02014.
   PubMed     Abstract available
   
   
   
4. JHA V
   Augmenting nephroprotection: balcinrenone plus dapagliflozin in chronic kidney disease.
   Lancet. 2025 Nov 8:S0140-6736(25)02126-9. doi: 10.1016/S0140-6736(25)02126.
   PubMed    
   
   
   
5. 
   Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.
   Lancet. 2025 Nov 7:S0140-6736(25)01853-7. doi: 10.1016/S0140-6736(25)01853.
   PubMed     Abstract available
   
   
   August 2025
6. PYNE L, Rossignol P, Giles C, Junek M, et al
   Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.
   Lancet. 2025;406:811-820.
   PubMed     Abstract available
   
   
   
7. SOOMRO QH, Charytan DM
   Requiem for mineralocorticoid blockade in maintenance dialysis.
   Lancet. 2025;406:780-782.
   PubMed    
   
   
   
8. ROSSIGNOL P, Zannad F, Massy Z, Azizi M, et al
   Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
   Lancet. 2025;406:705-718.
   PubMed     Abstract available
   
   
   
9. WALSH M, Collister D, Gallagher M, Mark PB, et al
   Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
   Lancet. 2025;406:695-704.
   PubMed     Abstract available
   
   
   May 2025
10. LOU-MEDA R, Perez JB
    Reducing the burden of chronic kidney disease in the world.
    Lancet. 2025 May 9:S0140-6736(25)00548-3. doi: 10.1016/S0140-6736(25)00548.
    PubMed    
    
    
    October 2024
11. RANCHIN B, Shroff R
    Haemodiafiltration improves survival in patients receiving dialysis.
    Lancet. 2024 Oct 25:S0140-6736(24)01938-X. doi: 10.1016/S0140-6736(24)01938.
    PubMed    
    
    
    August 2024
12. MARECEK R, Kissling S, Teso AD, Vuignier Y, et al
    Chronic metabolic acidosis in a patient with diabetes on maintenance haemodialysis: mind the anion gap.
    Lancet. 2024;404:570-571.
    PubMed    
    
    
    March 2024
13. WONG K, Pitcher D, Braddon F, Downward L, et al
    Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort.
    Lancet. 2024;403:1279-1289.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Renal Failure is free of charge.